Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance

... | May 31, 2023

Related Keywords

Japan ,United States ,Chicago ,Illinois ,American ,Helmy Eltoukhy ,Guardant Health ,Guardant Health Inc ,Linkedin ,American Society For Clinical Oncology ,Twitter ,Guardant Health On Linkedin ,Nasdaq ,Clinical Oncology ,Annual Meeting ,Guardant Infinity ,Nationwide Cancer Genome Screening Project ,Next Generation ,Guardant Reveal ,Nc Stock Exchange ,News ,Information ,Press Release ,Few ,Research ,Urther ,Onfirms ,Value ,F ,Interrogating ,Pigenomic ,Signals ,Ith ,Guardant ,Platform ,O ,Identify ,Novel ,Biomarker ,Targets ,End ,Redict ,Reatment Gh Us40131m1099 ,